Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 1644 of 5804
-
New heart valve device offers hope for patients with congenital defects
Disease control OngoingThis study will assess the safety and performance of the GORE PV1 Device for replacement of the pulmonary valve and reconstruction of the Right Ventricular Outflow Tract (RVOT).
Phase: NA • Sponsor: W.L.Gore & Associates • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
Sound waves vs. breast cancer: no scalpel needed?
Disease control Recruiting nowMonocentric prospective study evaluating the efficacy of High intensity focused ultrasound (HIFU) in breast tumors.
Phase: NA • Sponsor: Institut Bergonié • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
Custom vaccine shows promise in targeting aggressive breast cancer
Disease control CompletedThe purpose of this study is to learn more about how to treat patients with HER-2/neu positive invasive breast cancer (IBC). HER-2/neu is a type of protein that is known to be over-expressed in aggressive breast cancer. The study drug for this trial is DC1 study vaccine which is…
Phase: EARLY_PHASE1 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
Sickle cell drug voxelotor tested for Long-Term safety
Disease control TerminatedOpen Label Extension Study of Voxelotor Clinical Trial Participants with Sickle Cell Disease Who Participated in Voxelotor Clinical Trials
Phase: PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
Experimental antibody shows promise for rare amyloid disease
Disease control CompletedThis phase II trial studies how well isatuximab works in treating patients with primary amyloidosis that has come back or does not respond to treatment. Monoclonal antibodies, such as isatuximab, may interfere with the ability of cancer cells to grow and spread.
Phase: PHASE2 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated Jun 26, 2026 15:04 UTC
-
Experimental drug ruxolitinib joins standard therapy in brain cancer battle
Disease control CompletedThe purpose of this study is to test how well the drug works, safety and tolerability of an investigational drug called Ruxolitinib in gliomas and glioblastomas, when combined with standard treatment for brain cancer, temozolomide and radiation. Ruxolitinib is an experimental dr…
Phase: PHASE1 • Sponsor: Case Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
Blood pressure and eye tests may guide PTSD treatment
Symptom relief OngoingPosttraumatic stress disorder (PTSD) affects many individuals who experience a traumatic event. There are a variety of treatment options for PTSD, including psychotherapy (talk therapy) options, as well as medications, such as the drug prazosin. Each of the treatment options avai…
Phase: PHASE3 • Sponsor: VA Office of Research and Development • Aim: Symptom relief
Last updated Jun 27, 2026 09:05 UTC
-
Nerve repair breakthrough? tesamorelin trial aims to boost hand recovery
Disease control Recruiting nowThe aim of this clinical trial is to evaluate the efficacy of tesamorelin as a therapy for peripheral nerve injuries. The investigators hypothesize that treatment with tesamorelin will result in faster and more substantial recovery of motor and sensory function following surgical…
Phase: PHASE2 • Sponsor: Johns Hopkins University • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
CT scan clues may guide better liver cancer care
Knowledge-focused CompletedThis retrospective multicenter study aims to evaluate whether radiographic microvascular invasion (MVI) status can predict treatment response in patients with intermediate-stage hepatocellular carcinoma (HCC) receiving transarterial chemoembolization (TACE) combined with tyrosine…
Sponsor: First Affiliated Hospital, Sun Yat-Sen University • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:10 UTC
-
Artery-Saving surgery may reduce complications after esophageal cancer removal
Disease control CompletedThis randomized controlled trial evaluates the impact of preserving versus ligating the Right Gastric Artery (RGA) on postoperative anastomotic complications in patients undergoing McKeown minimally invasive esophagectomy (MIE) for esophageal squamous cell carcinoma. Specifically…
Phase: NA • Sponsor: The First Hospital of Hebei Medical University • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Fasenra proven safe for Long-Term asthma control in Real-World study
Disease control CompletedThe purpose of the investigation is to confirm the safety and efficacy under the post-marketing actual long-term use of FASENRA Subcutaneous Injection 30 mg Syringe.
Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 26, 2026 12:33 UTC
-
Double immune attack: new combo therapy targets Hard-to-Treat cancers
Disease control OngoingThis phase I trial studies the side effects and best dose of pembrolizumab and recombinant interleukin-12 in treating patients with solid tumors. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfer…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Zapping tumors with electricity: a new hope for pancreatic cancer?
Disease control Recruiting nowCompare the efficacy and tolerability of IRE in combination with either FOLFIRINOX or gemcitabine in patients with locally advanced pancreatic cancer.
Phase: PHASE1 • Sponsor: University of Louisville • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Triple-Drug immunotherapy cocktail shows promise in advanced tumors
Disease control CompletedThe purpose of this study is to demonstrate the safety and preliminary activity with triple combinations of relatlimab in combination with nivolumab and BMS-986205, or in combination with nivolumab and ipilimumab in immunotherapy-naive and pretreated populations across select adv…
Phase: PHASE1, PHASE2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New antibody combo aims to fight back against recurrent ovarian cancer
Disease control Recruiting nowThe main purpose of this study is to: * Learn about the safety of ubamatamab and to find out what dose of ubamatamab can be given alone or with cemiplimab to patients with ovarian cancer or cancer of the uterus * The study will also look at the levels of ubamatamab and/or cemipl…
Phase: PHASE1, PHASE2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Cholesterol drug may calm inflammation after heart attack
Disease control CompletedVascular and myocardial inflammation are significantly increased in Acute Coronary Syndrome (ACS) patients, are closely correlated to LDL-C levels, and are associated with these adverse consequences in the post-ACS patient population. Serum proprotein convertase subtilisin/kerin …
Phase: PHASE2 • Sponsor: Johns Hopkins University • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
Heart CT scans may spot clots missed by standard tests
Diagnosis CompletedThe aim of the AIS of HEARTS registry is to establish a database to collect, maintain and provide accessible individual patient data from international cohorts and to provide pooled analyses about the yield and value of cardiac computed tomography (CT), acquired during the initia…
Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) • Aim: Diagnosis
Last updated Jun 27, 2026 08:13 UTC
-
Lung cancer drug combo trial halted midway – what we know
Disease control TerminatedThis is a phase 3, open-label, 4-cohort study (3 randomized cohorts and 1 single-arm cohort). Participants enrolled in each cohort will be treated as detailed below. Each study cohort will be analyzed separately. Treatment will continue for up to 2 years, or until the patient exp…
Phase: PHASE3 • Sponsor: ImmunityBio, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
Your words could reveal your risk: AI analyzes speech to predict psychosis
Knowledge-focused Recruiting nowSubtle speech disorganization could be predictive of a transition to schizophrenia of ultra-high-risk patients. The aim of our longitudinal multicenter cohort study is to identify specific linguistic markers of the psychotic transition to validate a french predictive model of thi…
Sponsor: University Hospital, Brest • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
New drug combo aims to prevent deadly bowel blockages in ovarian cancer
Disease control CompletedOvarian cancer can often grow and cause obstructions in the bowel. These obstructions usually cannot be removed with surgery and can be fatal. This trial is testing whether a drug called cediranib can be used safely together with paclitaxel chemotherapy to treat ovarian cancer in…
Phase: PHASE2 • Sponsor: Prof Gordon Jayson • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC